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Abstract
The Orthopoxvirus genus of Poxviridae family is comprised of several human pathogens, including
cowpox (CPXV), Vaccinia (VACV), monkeypox (MPV) and Variola (VARV) viruses. Species of this
virus genus cause human diseases with various severities and outcome ranging from mild conditions
to death in fulminating cases. Currently, vaccination is the only protective measure against infection
with these viruses and no licensed antiviral drug therapy is available. In this study, we investigated
the potential of RNA interference pathway (RNAi) as a therapeutic approach for orthopox virus
infections using MPV as a model. Based on genome-wide expression studies and bioinformatic
analysis, we selected 12 viral genes and targeted them by small interference RNA (siRNA). Forty-
eight siRNA constructs were developed and evaluated in vitro for their ability to inhibit viral
replication. Two genes, each targeted with four different siRNA constructs in one pool, were
limiting to viral replication. Seven siRNA constructs from these two pools, targeting either an
essential gene for viral replication (A6R) or an important gene in viral entry (E8L), inhibited viral
replication in cell culture by 65-95% with no apparent cytotoxicity. Further analysis with wild-type
and recombinant MPV expressing green fluorescence protein demonstrated that one of these
constructs, siA6-a, was the most potent and inhibited viral replication for up to 7 days at a
concentration of 10 nM. These results emphasis the essential role of A6R gene in viral replication,
and demonstrate the potential of RNAi as a therapeutic approach for developing oligonucleotide-
based drug therapy for MPV and other orthopox viruses.
Background
Monkeypox virus (MPV) was first identified in laboratory-
maintained cynomolgus monkeys [1]. The virus is
believed to have been circulating for a long time in
numerous animal hosts, including squirrels, in central
and western Africa. Early human infections with MPV,
which was recognized in Zaire and later in Liberia and
Sierra Leone, occurred through direct contact with
infected animals [2]. However, person-to-person trans-
mission was reported more recently [3]. Monkeypox dis-
ease manifestation is similar to that of smallpox, but with
lower case fatalities and more localized pustular rash dis-
tribution [4]. Because vaccination against smallpox ceased
in early 1980s after the disease was declared eradicated
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[5], current public immunity towards poxviruses is
deemed non-protective and younger generations are con-
sidered completely immune naive. Thus, a surprising nat-
ural, incidental or deliberate release of virulent
monkeypox or other orthopox viruses poses a serious
threat to public health. Currently, there are no licensed
drugs to treat poxvirus infections, and use of antiviral
Cidofovir and ST-246 [6] may gradually erode with emer-
gence of resistant viral strains [7,8] or further identifica-
tion of limiting drug side effects [6,9]. Therefore, the need
for new effective drugs and novel therapeutic strategies
that can withstand field application challenges is para-
mount.
RNA interference (RNAi) is a natural mechanism for gene
expression regulation and protection against insertion of
foreign RNA in plant and mammalian cells [10]. RNAi-
based studies have been particularly valuable in elucidat-
ing gene functions in a variety of prokaryotic and eukary-
otic organisms [11]. Recent advances in siRNA delivery
systems and selective targeting methodology leveraged the
prodigious utility of the RNAi pathway as a therapeutic
approach for infectious, neurodegenerative, cancer, and
hereditary diseases [12].
The use of RNAi pathway as a new approach in antiviral
drug discovery is particularly promising because viruses
have relatively small genomes with a limited number of
targetable genes. Furthermore, genetic distance between
mammalian and viral genomes represents an advantage in
minimizing off-target hits and reducing possible side
effects [13]. Recent studies utilized RNAi to silence spe-
cific viral genes and identify its function [14], or to inhibit
viral replication [15]. In this study, we developed siRNAs
to target several monkeypox viral proteins, and demon-
strated the application of this approach in identifying new
drug targets and inhibiting viral replication in cell culture.
Results
Selecting MPV genes targets and screening siRNA
Monkeypox virus genome consists of 196,858-base pairs
(bp) with 190 open reading frames of 60 amino acid res-
idues or more [16]. Like other orthopox viruses, the MPV
genome encodes for a number of enzymes and factors that
are necessary for entry, self-replication, and maturation.
The central region of the genome contains highly con-
served genes that are essential for viral replication, and ter-
minal regions contain less conserved genes that are
important for virus-host interactions. In designing siRNA
molecules, we selected 12 gene targets based on their tem-
poral expression and functional significance, e.g., attach-
ment, replication, and host immune modulation (Table
1). These targets varied in size from 132 to 3021 bp, and
mapped to the region between 22056 and 114223 on
MPV genome covering most of the conserved region.
Custom SMARTpool software (Dharmacon) was selected
to design four siRNA sequences for each of the 12 selected
MPV genes. Constructs of 19-21 nucleic acids were chem-
ically synthesized and pooled at comparable concentra-
tions to maximize efficacy. Screening was performed in
rhesus macaque kidney epithelial cells (LLC-MK2). This
cell line was selected based on experimental transfection
efficiency, host relevance, and ability to support replica-
tion of used MPV isolate.
For a preliminary evaluation of antiviral properties of the
12 siRNA pools, cultured LLC-MK2 cells in 24 wells plate
were transfected with each of the multiplexed siRNA pools
at 100 or 200 nM overnight. Cells were then infected with
100 pfu/well of MPV-KK. Infected cells were incubated for
48 h post infection (PI) at which time the cells were har-
vested and viral titer was measured by using the plaque
assay. Percentage of viral replication rates in siRNA-trans-
fected cells relative to replication in mock-transfected cells
are shown in Fig 1. Inhibition of viral replication varied
significantly based on targeted gene and used siRNA con-
centrations. For example, while anti-L5 siRNA pool
showed little or no effect on viral replication at 100 nM,
pools targeting A6R gene (siA6) or E8L gene (siE8) exhib-
ited 95% and 78% at 100 nM respectively (Fig. 1). Differ-
ences in inhibition potency of siRNA polls at high 200 nM
concentration were less pronounced generally, and most
pools showed more than 50% inhibition.
Because transfection with siRNAs can be cytotoxic, espe-
cially at high concentrations [17], and consequently will
affect viral replication [18], we examined the morphology
of transfected cells using phase-contrast light microscopy
and followed emergence of any cytopathic signs such as
changes in the refractive index or cytoplasmic shrinkage of
the cells. Alternatively we used vital dyes, such as Trypan
blue. No signs of cytotoxicity were observed in cells
treated with all tested siRNA pools at 100 nM, and only
three out of the 12 siRNA pools induced 15-35% decrease
in cells viability after 72 h of transfection at concentration
of 200 nM (data not shown).
Identifying the most potent single siRNA construct from 
inhibitory siRNA pools and defining its IC50
Each of the two siRNAs that exhibited the most significant
inhibition of viral replication, siA6 and siE8, consisted of
a pool of four different siRNA sequences that targeted var-
ious regions of the A6R and E8L genes (Table 2). Hence,
we anticipated that each construct of the two pools will
have different antiviral properties. To identify the most
potent sequence within the two pools, we transfected
LLC-MK2 cells with each of the siRNA sequences individ-
ually at concentration of 40 nM for 18 h. Transfected cells
were infected with MPV-KK, and viral replication was eval-
uated 48 h PI. All four sequences of siA6 pool severelyVirology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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inhibited viral replication, with siA6-a and siA6-b being
the most potent, achieving more than 95% inhibition.
Interestingly, treating cells with the siA6 pool didn't result
in appreciably stronger viral inhibition than treatment
with the most potent siA6-a alone. The antiviral properties
of siRNA sequences targeting E8L varied significantly and
while siE8-d inhibited viral replication by more than
90%, siE8-c exhibited only a little more than 20% inhibi-
tion (Fig. 2).
To characterize the antiviral properties of most potent
siRNA constructs, namely siA6-a and siE8-d, LLC-MK2
cells were transfected with one fold serial dilution of each
construct to cover a range of 40 to 1.25 nM in six concen-
trations. Overnight transfected cells were infected with
MPV at 100 pfu/well and viral replication was examined
at 48 hours PI (Fig 3). siA6-a showed average viral replica-
tion inhibition of 23% at the lowest tested concentration
of 1.25 nM, and complete inhibition at concentrations of
20 nM and higher. In agreement with previous assays,
siE8-d maintained weaker antiviral activity than siA6-a
and concentrations of ≤ 2.5 nM were inefficacious. The
estimated IC50 for siA6-a would be less than 5 nM under
the experimental conditions described above.
We used 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) to measure the effect of siA6-a and
siE8-d on cells viability. Transfected mock-infected cells
that had been handled identically to virus infected cells
maintained more than 90% viability at all siA6-a or siE8-
d concentrations (Fig. 3).
siA6-a exhibits a surprising in vitro half life
We used MPV expressing green fluorescence protein
(MPV-GFP) [19] to reproduce the results obtained using
wild-type MPV-KK, examine the relationship of viral rep-
lication rate and virucidal properties of siA6-a or siE8-d,
and to assess the stability of these two siRNA constructs
over extended culture. Cells were transfected for 18 h with
either siA6-a or siE8-d at the same concentration range
described above. Transfected cells were infected with 2000
pfu/well of MPV-GFP, and viral replication was followed
for 7 days PI by measuring fluorescence increase of the
culture once every 24 h. Controls of untransfected-
infected, transfected-uninfected, and non-targeting scram-
bled siRNA transfected-infected cells were included for
results normalization and to confirmation of siRNA spe-
cificity. Consistent with plaque assay results obtained
from wild-type MPV, the viral replication rates in cells
Table 1: Selected siRNA Targets
MPV ORF VACV ORF Gene size(bp) Region Known or predicted function
A5L A4L 846 113340-114185 39 kDa immunodominant virion core protein needed for the progression of IV to 
infectious IMV
A6R A5R 486 114223-114708 Precursor of RNA polymerase 22 kDa
C14L F8L 195 35828-36022 No information available
C2L K2L 1128 26384-27511 Serine protease inhibitor-like, SPI-3; inhibition
of the ability of infected cells to fuse
C3L K3L 132 27672-27803 Interferon resistance; host defense modulator
E8L D8L 915 103116-104030 IMV cell attachment, putative; blockage causes plaque reduction
F8L E9L 3021 53691-56711 DNA polymerase, catalytic subunit
H1L H1L 516 87256-87771 Tyrosine/serine protein phosphatase; blocks IFN-γ
H3L H3L 975 88358-89332 IMV cell attachment; heparin binding surface protein involved in IMV maturation
I3L I3L 810 61085-61894 Virosomal ssDNA-binding phosphoprotein; interacts with R2 subunit of 
ribonucleotide reductase
L5L J5L 402 82891-83292 Essential for virus multiplication
P1L N1L 354 22056-22409 Virokine; host defense modulator
Selected MPV gene targets for siRNA development with gene size, location across MPV genome, and known or predicted function of its orthologs 
in VACV.Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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transfected with scrambled non-targeting siRNA and in
mock-transfected cells (Fig. 4A, D upper panel) were iden-
tical. No increase in fluorescence was observed in cells
transfected with siA6-a at concentrations of 40 and 20 nm,
which resembled the results observed in cells treated with
100 μM Cidofovir (not shown). Furthermore, viral repli-
cation rate was kept at less than half of its values in control
cells as late as 7 days PI in cells treated with 10 nM of siA6-
a, and only concentrations ≤ 5 nM exhibited mild or no
viral inhibition (Fig. 4b, D middle panel). These results
highlight the unusual stability of siA6-a construct and
confirm its antiviral function regardless of virus replica-
tion rate. In contrary to our finding while using wild-type
MPV, cells treated with siE8-d were more permissive to
MPV-GFP replication and sharp increase in fluorescence
was detected in cells treated at concentration ≤ 20 nM
across all PI time points (Fig. 4C), and significant viral
replication was observed at concentration of 40 nM (Fig,
4C, D lower panel). This variation in antiviral properties
of siE8-d and dependence on experimental conditions
was likely due to the known gradual decline of siRNA sta-
bility during extended incubation duration. The use of
MPV-GFP required relatively long incubation period to
reach the exponential phase of fluorescence amplification
needed for adequate assessment of viral replication.
Examination of transfected cells by phase contrast micro-
scopy showed no cytopathic signs, underscoring the spe-
cific antiviral properties of siA6-a.
Inhibition of MPV replication by siA6-a is MOI dependent
Successful siRNA application in the treatment of diseases
depends on a variety of parameters, including stability of
the siRNA, effective delivery, and efficacy against a high
viral burden [20,21]. Stable and potent siRNA may have
indications for post onset treatment as well as prophy-
laxis. We evaluated the antiviral properties of siA6-a
through multiplicity of infection (MOI) range of 4 to
0.005. Our results showed that LLC-MK2 cells transfected
with 20 nm of siA6-a remained refractory to viral replica-
tion after 8 days of MPV infection at an MOI of 0.01 or less
(Fig. 5). Under identical conditions, siA6-a showed more
than 50% inhibition of MPV-GFP replication at MOI of
0.1 in day 6 PI. Optimizing uptake and nuclease resistance
properties of siA6-a, through chemical modifications that
introduce lipophilic moieties and other chemical groups,
would produce more potent derivatives that cover wider
MOI range and last for longer durations [22].
Discussion
Despite the outstanding success of vaccination in eradicat-
ing smallpox, the process was underlined with significant
adverse reactions including inadvertent inoculation, ocu-
lar vaccinia, generalized vaccinia, eczema vaccinatum,
progressive vaccinia, postvaccinial encephalopathy and
Representative results from screened siRNA pools designed  to specifically target selected MPV genes Figure 1
Representative results from screened siRNA pools 
designed to specifically target selected MPV genes. 
MK2 cells were transfected with a set of four multiplexed 
siRNA constructs targeting a single gene at a time. Parallel 
control cells were transfected with scrambled siRNAs under 
identical conditions to ensure antiviral specificity. Preliminary 
siRNA pools evaluation was carried at concentrations of 100 
and 200 nM. Transfected cells were infected with MPV, and 
viral replication was assayed after incubation for 48 h by 
plaque assay. Presented results are relative to viral replica-
tion in mock-transfected cells ± one standard deviation. Mul-
tiplexed siRNA pools targeting A6R and E8L genes, i.e., siA6 
and siE8, exhibited a strong dose-dependent antiviral effect 
with no or negligible toxicity at both concentrations.
Identifying the most potent antiviral siRNA construct within  siA6 and siE8 pools Figure 2
Identifying the most potent antiviral siRNA con-
struct within siA6 and siE8 pools. MK2 cells transfected 
with 40 nM of one of the four constructs multiplexed in siA6 
or siE8 pools, i.e., siA6R-a, -b, -c, -d or siE8L-a, -b, -c, -d. 
Transfected cells were infected with MPV and viral replica-
tion was determined at 48 h PI using plaque assay. Results are 
presented as a percentage of average plaque counts in 
treated cells to that in mock transfected control cells. siA6-a 
and siE8-d showed the strongest antiviral effect.Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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encephalomyelitis, and fetal vaccinia. These complica-
tions can occur among primary vaccinated individuals or
in secondary patients who are accidentally inoculated
upon their contact with vaccinated individual [23,24].
Resorting to vaccine as a response measure to sudden pox-
virus release is undermined further by increasing preva-
lence of immuno- compromised individuals and delayed
immune protection inherent to vaccination. Broad use of
vaccinia immune globulin (VIG) is hampered by its lim-
ited accessibility; hence, adhering to developing a chemi-
cal agent that is effective and safe for use in PI and
chemoprophylaxis purposes presents a more favorable
approach. While Cidofovir [25] and ST-246 [8] remain
the drugs of choice for poxvirus infections, known side
effects or propensity to develop resistant viral strains dic-
tate cautious use [8,26,27].
In this study, we showed that RNAi can be used as a potent
approach to reduce MPV replication in a sequence-specific
manner. We screened 48 siRNA constructs in 12 pools tar-
geting 12 monkeypox genes and examined their effect on
viral replication. We showed that the siRNAs affected MPV
replication in various degrees. Two siRNA pools exhibited
substantial antiviral properties and reduced viral replica-
tion to less than 10% of its propagation in control
untreated cells. A single siRNA construct targeting A6R
gene suppressed viral replication to near completion with
IC50 less than 10 nanomoles.
The observed disparity in siRNA efficacy among screened
pools is consistent with a number of previous reports
[28,29]. Although reasons for this variation are still not
fully understood, it is accepted that delivery of siRNA in
its optimal functional concentration to targeted cells, and
other unpredictable sub-cellular events such as concentra-
tion of siRNA in endosomes or trapping in other vesicles
are major causes of variation in siRNA efficacy studies
[30]. Furthermore, larger forms of RNA undergo a number
of sequential processing steps before they interact with
RNAi machinery and achieve the intended biological
function. This include processing of miRNA and shRNA
by Dicer, assembly of resultant guide strand into the RNA-
induced silencing complex (RISC), recognition of target
viral RNA sequences and cleavage of targeted mRNA.
Because these steps involve interactions of various second-
Table 2: Sequences of siRNA constructs in the siRNA pools targeting A6R, and E8L genes.
Targeted MPV gene Used name siRNA sequence
E8L siE8L-a CGACAATAGTGTTCTGAAT
siE8L-b CGAATATCGTTGACTCATA
siE8L-c GCGCAGACATATTAGCGGA
siE8L-d GAATAGCGGTGAGTATAAA
A6R siA6R-a GAGAATTGTTGTCGGTAAA
siA6R-b TGAAATAGCGGGTATAATA
siA6R-c GCTCTTAAACGACGCTATA
siA6R-d GTCCTATAGTCATCGAAAA
Each sequence consists of 19 nucleotides.
Sequence of the most effective antiviral siRNA pools. Eight sequences each consists of 19 nucleotides with UU overhang were developed to target 
A6R, or E8L MPV genes. Sequences were BLAST searched against GenBank database to reduce potential for interference with host, off target 
effects, and optimize specificity.
Dose-response of siA6-a and siE8-d Figure 3
Dose-response of siA6-a and siE8-d. MK2 cells were 
transfected with either siA6-a or siE8-d at six different con-
centrations ranging between 40 to 1.25 nm. Transfected cells 
were infected with MPV and viral titer was identified at 48 h 
PI by plaque assay. Results (bars) are expressed as a ratio of 
the average plaque counts from treated wells to counts in 
parallel mock-transfected cells ± one standard deviation. 
Toxicity of both constructs were examined under identical 
conditions using (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphe-
nyltetrazolium bromide) in MTT assay. Results (lines) are 
normalized to viability of mock-transfected control cells (sec-
ondary Y-axis). Transfected cells maintained over 90% of 
their viability across tested range of siRNA concentrations, 
highlighting siRNA specificity and low toxicity.Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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Inhibition of MPV-GFP replication by siA6-a and siE8-d Figure 4
Inhibition of MPV-GFP replication by siA6-a and siE8-d. Cells transfected with various concentrations of scrambled 
non-targeting siRNA (A), siA6-a (B) or siE8-d (C) were infected with MPV-GFP, and viral replication was followed for 7 days PI 
by measuring the fluorescence increase in culture. (A) Cells treated with scrambled siRNA did not exhibit any antiviral activity 
and viral replication was similar to mock-transfected cells. (B) siA6-a maintained its potent antiviral activity up to 7 days PI in 
concentrations higher than 10 nm. (C) Inhibition by siE8-d was significant only at 40 nm with rapid degrading activity reflecting 
relative low stability. (D) Randomly picked images from virus infected-transfected cells at day 6 PI. Comparable fluorescence in 
cells transfected with scrambled siRNA at concentrations of 40 nm or less (upper panel). Cells transfected with siA6-a at con-
centrations of 10 nm or more did not show significant increase in fluorescence (middle panel), similar to those treated with 
100 μM of Cidofovir (not shown) underscoring the potent antiviral function of siA6-a. Cells treated with siE8-d showed signif-
icant viral replication at concentrations of 20 nm or less as indicated by fluorescence intensity similarity with cells treated with 
scrambled non-inhibitory siRNA (last panel). Uninfected-transfected cells remained viable and no signs of cytopathy were 
detected until the end of the experiment (not shown).Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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ary molecular conformations defined by diverse primary
sequences they are likely to exhibit unequal efficiencies,
which would factor into the observed variation in siRNAs
potency. Thus, identifying an effective siRNA empirically
remains a common tool in therapeutic applications of
RNAi [31].
It is important to note that screened siRNA pools may
have silenced the targeted genes, but without producing a
phenotype or influencing MPV replication. This is essen-
tially defined by the function of the targeted gene. Pres-
ence of viral or host compensating mechanisms for the
function of knocked-down gene would obfuscate evalua-
tion of siRNA efficacy further [32], especially when reduc-
tion or inhibition of replication is the endpoint in
assessing siRNA potency. Alternatively, multiple genes
with varied copy number [33] are found to contribute to
the same phenotype or trait with different intensities.
Using siRNA and reverse genetics to silence one or more
of these genes and determine its function is intrinsically
difficult. Similarly, genes associated with high translation
turnover duration [34] or highly efficient protein synthe-
sis mechanisms can sustain viral replication at low copy
number. Nevertheless, our results provided reverse genetic
evidence for the vitality of A6R and E8L in MPV replica-
tion, and further work is needed to clarify the knockdown
of the other targets at the gene or protein level.
Poxvirus is the only known double-stranded DNA viral
family that propagates in host cytoplasm and encodes
most of the enzymes and factors necessary for transcrip-
tion and replication of its material [35]. Once the virus
enters into the host cytoplasm, it becomes uncoated to
release its genetic information and component of early
transcription system packaged within the core of the vir-
ion [36,37]. Many targeted RNA sequences will interact
with viral and/or cellular proteins which would hamper,
if not prevent, the ability of RNA-induced silencing com-
plex to recognize its viral targets [38]. This may contribute
to the variation we observed in the efficacy of single siRNA
constructs within the same pool as in the case of siE8-d
and siE8-c which target the same E8L gene.
The function of siA6-a and E8-d targets in MPV remain
unidentified; however, their orthologs in vaccinia, A5R,
and D8L, function as a precursor of RNA polymerase [39]
and cell attachment protein [40]. Mutant vaccinia virus
with dysfunctional A5 or D8 genes show no or severely
perturbed viral replication. Soluble vaccinia D8 protein,
which binds chondroitin sulfate (CS), interferes with
adsorption of wild-type vaccinia and decreases viral prop-
agation rate. The significant decrease of MPV replication
in siE8-d treated cells, and the disruptive effect of soluble
D8 on vaccinia adsorption with consequent lower rates of
replication imply a sort of similarity in both gene func-
tions and suggests possible role for CS in MPV cell entry.
The presence of alternative MPV cell-attachment and
adsorption mechanisms, such as binding of A27L protein
with cell heparan sulfate HS described in vaccinia [41],
may account for the incomplete replication inhibition of
MPV replication despite knock-down of E8 gene.
Persistence of RNAi occurs for short period of time mainly
due to the relatively short half life of siRNA and lack of an
amplification mechanism in mammalian cells. The esti-
mated 66 hours of RNAi persistence is relatively short due
to siRNA hydrolysis and dilution over the course of cell
division [42]. Recently D5R gene in vaccinia virus strain
Western Reserve was introduced as a valid siRNA target in
vitro[43]. Targeting this gene in vaccinia WR, CPV, and
MPV led to 70% inhibition of viral replication at nanomo-
lar levels of siRNA using different cell lines. The same
work report an impressive prolonged prophylactic antivi-
ral effect that lasted for 72 h at concentration of 100 nm.
Surprisingly, our siA6-a maintained solid viral replication
inhibition for more than 7 days PI in cell culture at con-
centration of 20 nm. This unusual stability may be due to
a unique molecule tertiary structure and/or highly sensi-
tive target. Further work is under way to access the phar-
macokinetics of A6-a construct and address this point.
The antiviral effects of 20 nm of siA6-a and 100 nm of
Cidofovir were comparable and seem to inhibit the repli-
cation of all virus forms. These two drugs target the virus
directly by silencing gene expression or interfering with
MOI-dependent siA6-a inhibition of MPV replication Figure 5
MOI-dependent siA6-a inhibition of MPV replication. 
Transfected MK2 cells with 20 nM of siA6-a were infected 
with MPV-GFP at MOIs of 0.001, 0.01, 0.1. Viral replication 
was traced by measuring the fluorescence increase in culture 
over duration of 7 days PI. Curves in dashed lines and empty 
markers represent siA6-a treated cells. Curves in solid lines 
and filled markers are mock transfected. siA6-a remained 
effective in cells infected with MPV at MOI of 0.01 for 8 days 
PI.Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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vDNA replication without perturbing host cell biology.
However, easy synthesis and adjustment of siRNA
sequence represent an extra advantage over other chemi-
cally synthesized drugs. This, in addition to recent
advancements in sequencing capabilities and bioinfor-
matics, enabled unprecedented flexibility to readapt
siRNA molecules to function on any emerging resistant
viral strains, enhance siRNA specificity, and reduce poten-
tial side effects. These tasks are made easier when the tar-
geted microorganism and its host are genetically different.
In our case, siA6-a didn't induce any signs of cytotoxicity
and seemed not interfere with host cell biology even when
used at concentrations up to ten times its IC50.
An alternative approach for developing antiviral drugs tar-
gets specific host functions necessary for viral replication.
A good example of this class of targets is the epidermal
growth factor receptor family of tyrosine kinases [44],
which disrupt viral maturation and replication cycle when
antagonized. A member of this family (ErbB-1) was inhib-
ited by CI-1033, a drug that has been developed originally
for its anticancer properties, and led to significant reduc-
tion in poxvirus activity [45]. However, CI-1033 seems to
be more specific in targeting IMV and not EEV forms. This
was evident from the described reduction in the size and
not overall plaque count, and from the synergistic antivi-
ral effect observed in cells co-treated with neutralizing
virus antibodies and CI-1033. It remains unclear how
inhibiting ErbB would affect host homeostasis. The com-
plete inhibition of MPV replication by targeting A6R gene
suggests that, unlike CI-1033, siA6-a acts on an indispen-
sable viral function at a stage upstream to viral differenti-
ation into distinct forms, and abolishes virus replication
regardless of its form.
In conclusion, using RNAi pathway we identified two
MPV genes that serve as potential drug targets during
infection in cell culture. A6R and E8L genes of MPV were
antagonized effectively using siRNA molecules, and con-
structs siA6-a and siE8-d disrupted MPV replication
severely. siA6-a construct exhibited considerable stability
and promising antiviral potency with IC50 less than 10
nm. Chemical modification study aiming to enhance A6-
a stability and development of suitable siRNA delivery
system are needed before assessing siA6-a in animal mod-
els.
Materials and methods
Viruses and cultures
Wild-type monkeypox virus, strain Katako Kombe (MPV-
KK) and MPV expressing green fluorescent protein (MPV-
GFP) were used to evaluate siRNA efficacy [19]. The
viruses were propagated in Vero E6 cells maintained in
Eagle's minimum essential medium with non-essential
amino acids (EMEM/NEAA) supplemented with 2 mM L-
glutamine, 10% of heat-inactivated fetal bovine serum
(FBS), 10 mg/L Gentamycin, 250 μg/L Fungizone, and
buffered with 10 mM HEPES [46]. Viral titers were deter-
mined by the plaque assay as described in [29]. Briefly,
monolayers of confluent Vero-E6 cells in six-well plates
were overlaid with 100-200 μl aliquots of serial dilutions
of examined viral sample in triplicate. The virus was
allowed to absorb for 1 h at 37°C with gentle mix for 30
sec each 15 min. Two to three ml of complete culture
medium was added to each well, and plates were incu-
bated until the development of clear plaques (≈ 4-5 days).
Stock solution of 1.3 g/L of crystal violet, 30% formalin,
and 5% ethanol was diluted with PBS (1:2) and used to fix
and stain the cells. Plates were incubated 15-20 min at
room temperature to allow clear staining. Cells were
rinsed gently with PBS and plaques were counted on a
light box.
For experiments involving MPV-GFP, plates were infected
with 2000 plaque-forming units (pfu) per well unless oth-
erwise indicated. Fluorescence readings were taken every
24 h by using a Gemini EM fluorescence reader and Soft-
max 4.7 software (Molecular Devices, Union City, CA).
The results were normalized to average fluorescence in
control cells. Data were expressed as means ± SD. Statisti-
cal analysis was performed using Student's t-test when
appropriate.
siRNA design, preparation, and transfection
Chemically synthesized siRNAs were custom-designed to
target selected MPV genes by Dharmacon (Chicago, IL).
siRNA sequences were BLAST-searched against the human
genome database to assess possible cross-reactivity. For
each targeted gene, four siRNAs were synthesized and
pooled. Dried siRNA pools were reconstituted in rehydra-
tion buffer (100 mM KCl, 30 mM HEPES pH 7.5, 1 mM
MgCl2) to a final concentration of 100 μM and stored at -
80°C until used.
LLC-MK2 cells were used to evaluate the efficacy of the
siRNAs. Confluent cells were briefly trypsinized, counted,
and resuspended in culture medium at desired concentra-
tion. Cell suspension was used to seed 24-well culture
plates (Costar, Lowell, MA), and plates were incubated for
24-48 h to allow multiplication of cells in antibiotic- and
Fungizone-free medium before infection with virus. To
transfect the cells, siRNA and the transfection reagent were
complexed as recommended by the manufacturer (Dhar-
macon, Chicago, IL). Briefly, equal volume of 10× solu-
tion (relative to the final intended concentrations) of
siRNA and transfection reagent were prepared and mixed
together. The resultant 5× solutions mix was incubated for
30 min at room temperature to allow the formation of
siRNA transfection complex. This was diluted to the
intended final 1× concentration using OPTI-MEM-I (Inv-Virology Journal 2009, 6:188 http://www.virologyj.com/content/6/1/188
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itrogen, Carlsbad, CA). Cells were washed twice gently
with 0.5 ml of OPTI-MEM-I buffer and incubated with 1×
transfection siRNA complex for 12 to 16 h prior to viral
infection.
Cells infection with virus
To infect siRNA transfected and non transfected control
cells with MPV, incubation medium was replaced by the
virus inoculum diluted to produce the desired MOIs using
OPTI-MEM-I (GIBCO-Invitrogen, Carlsbad, CA). Cells
were incubated with the virus seed for 30 min at room
temperature to allow viral absorption, and gentle 15-sec
shake every 10 min was done to ensure even viral distribu-
tion. Removed culture medium was added back, and cells
were incubated in 93-95% relative humidity atmosphere
at 37°C, 5% CO2.
Toxicity assay
Cells viability was assessed using MTT Cell Proliferation
assay (ATCC, Manassas, VA). Briefly, 10 μl of MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
was added to each well and the plates were incubated at
37°C, 5% CO2  until clear purple crystals precipitant
appeared in cells cytoplasm (4-8 h). Cells were lysed by
adding 100 μl of detergent (proprietary, ATCC kit) and
incubated overnight or until the purple crystals were dis-
solved. Color intensity was measured by spectrophotom-
eter (Tecan, Pittsburgh, PA) at 570 nm, and cytotoxicity
was calculated as a ratio of absorbance in treated versus
untreated cells.
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